An affiliate of TWST has filed a notice of proposed sale of 167 shares of common stock, with an aggregate market value of $14,248.64, expected to be sold on or after August 3, 2026 on NASDAQ. These shares relate to restricted stock vesting dated July 31, 2026, received as compensation from the issuer. The filing also lists prior sales of common stock over the past three months by Robert F. Werner, including blocks of 4,961, 1,359, and other smaller transactions in May and June 2026.
Twist Bioscience reported record fiscal Q3 2026 revenue of $118.4 million, up 23% year over year and marking its 14th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose to $56.6 million and NGS Applications to $61.8 million, with both segments growing sequentially. Gross margin improved to 52.8% from 51.6% in the prior quarter.
The company posted a net loss of $35.1 million, or $0.56 per diluted share, versus prior-year net income of $20.4 million that included a $48.8 million gain from the Atlas Data Storage spin-out. Adjusted EBITDA was $(11.3) million and cash, cash equivalents and short-term investments totaled about $167 million as of June 30, 2026. Management raised full-year 2026 revenue guidance to $456–$457 million, approximately 21% growth, and expects Q4 revenue of $123–$124 million with adjusted EBITDA breakeven.
Twist Bioscience Corp President and COO Patrick John Finn sold 2,238 shares of common stock on July 23, 2026 at $93.893 per share to cover tax withholding from vesting Restricted Stock Units. These mandated "sell to cover" sales were non-discretionary under the company’s equity incentive plans, leaving him with 272,566 directly held shares.
An affiliate of TWST filed a notice to sell 2,238 shares of common stock through Fidelity Brokerage Services on 07/23/2026 on NASDAQ, with an indicated value of $210,132.53. The shares relate to restricted stock vesting on 07/22/2026, treated as compensation.
The filing also lists prior sales in the past three months by Patrick Finn: 2,321 shares for $141,026.51 on 04/23/2026, 2,844 shares for $162,531.19 on 05/04/2026, and 4,160 shares for $221,547.45 on 05/21/2026.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,399 shares of common stock on July 9, 2026 at $94.334 per share. According to the disclosure, the sale was required to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Laponis directly holds 110,276 shares of Twist Bioscience common stock.
TWST-related filing: A Form 144 notice reports insider sales of Common stock by Adam Laponis. The filing lists multiple dispositions during April–May 2026 with per-trade share counts and proceeds recorded. It also shows a planned/security line item for Common with a 07/08/2025 vesting reference.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 18,880 shares of common stock at $95.00 per share on June 25, 2026. After this sale, she directly holds 824,039 common shares. The filing also lists outstanding employee stock options, including 16,470 options exercisable at $8.82 expiring in 2027 and 64,950 options at $67.85 expiring in 2030. The transactions were made under a pre-established Rule 10b5-1 trading plan.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of Common Stock. On June 24, 2026, Cho sold 14,205 shares at $89.75 per share. After this transaction, he continues to hold 105,141 shares directly.
The filing notes that this sale was carried out under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026, indicating the trade was pre-planned rather than timed at discretion, which often signals routine portfolio management rather than a change in outlook.
Emily M. Leproust reported a series of sales of common stock between 04/21/2026 and 06/22/2026.
Transactions listed include 24,282 shares on 05/26/2026 for $1,580,245.85 and 25,017 shares on 05/27/2026 for $1,633,407.46, along with multiple other dated sales and dollar amounts shown in the filing.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported a small mandated share sale tied to equity compensation. On June 22, 2026, she sold 291 shares of common stock at $87.3224 per share solely to cover tax withholding on vesting Restricted Stock Units. After this tax-related transaction, she directly held 120,414 shares of Twist Bioscience common stock.